

Martin Lipkin, M.D.
Active Member
AACR Member Since 1963

Dr. Lipkin submitted the following biography, which noted he has been a faculty member at the Cornell Medical Center throughout his academic career. His main activities have involved developing and carrying out new research programs in several academic disciplines. On the basis of this experience, he became a Nominator for the Nobel Prize in Physiology or Medicine.

When he began his academic career as a Research Fellow at the Cornell University Medical College, he initiated a new academic field by demonstrating the first automated correlation and processing of medical information published in the journal *Science* in 1957, and in a further series of studies he introduced computers into clinical medicine and medical research. He then carried out a series of studies in a newly emerging area of human biology and was the first to identify human cells synthesizing DNA, and the phases of the cell cycle and kinetics of cell renewal in humans. From these findings, he developed a molecular multi-step model of carcinogenesis and a series of cellular biomarkers associated with the evolution of cancer. He simultaneously developed the first comprehensive high-risk registry of individuals with increased susceptibility to colon cancer, and with it the first basic-clinical translational research project at Memorial Sloan-Kettering Cancer Center.

His development of this new ability to study cellular biomarkers in individuals with increased cancer susceptibility enabled investigators to study large numbers of new potential chemopreventive agents, and this made possible a broad expansion of human clinical trials in the cancer chemoprevention field.

He was responsible for the first textbook on cancer chemoprevention by nutritional and pharmaceutical chemopreventive agents, and the first textbook on the subject of gastrointestinal cancer. He also carried out the first study demonstrating that increasing dietary calcium and vitamin D had efficacy as potential chemopreventive agents to inhibit human benign and malignant colonic tumors, and he produced the first textbook on calcium, vitamin D and cancer prevention. In recent years his studies have focused on the chemopreventive inhibition of tumors in preclinical wild type and genetically modified rodent models.

Dr. Lipkin has served as chairperson of the AACR Cancer Prevention Committee, on the editorial boards of *Cancer Research* and *Cancer*

Epidemiology, Biomarkers & Prevention, and his advances in cancer research have been featured on Cancer Research covers on two occasions.

He was a founding member of the National Cancer Institute's original Organ Site Program and NCI's National Large Bowel Cancer Project where he became Director of its Executive Committee. He is a member of the American Society for Clinical Investigation, American Physiological Society, American Gastroenterological Association and other professional organizations. He was a founding member and director of the International Society of Investigative Gastroenterology, the Digestive Disease Foundation, and Chairman of the Scientific Program Committee and the Educational Committee of the Medical Society of the State of New York.

He has also been a member of the American Cancer Society's Council on Analysis and Projection, the American Medical Association's Committee on Diagnostic and Therapeutic Technology Assessment, and the Internal Medicine Advisory Board of the Joint Commission on Accreditation of Hospitals.